CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT imaging for metastatic triple-negative breast cancer
Official title: Prospective Phase 0 Pilot Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
Run by Institut Cancerologie de l'Ouest · NCT06962163 · Data updated 2026-11-12
This study will test whether a CXCR4-targeted PET/CT scan ([68Ga]Ga-PentixaFor) can better detect metastatic triple-negative breast cancer than the standard [18F]FDG PET/CT in adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Institut Cancerologie de l'Ouest Academic / other |
| Locations | 1 site (Saint-Herblain) |
| Status | Recruiting |
| Started | December 5, 2025 |
| Main results expected | June 2027 |
| Study ends | June 2030 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT06962163 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with histologically confirmed triple-negative metastatic breast cancer and at least one measurable metastasis on prior imaging, with ECOG performance status below 2, are eligible.
✕Probably not a fit
Patients whose tumors do not express CXCR4 or who cannot undergo PET/CT (for example, pregnant patients or those with prohibitive comorbidity) are unlikely to benefit diagnostically.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial uses a CXCR4-targeted radiotracer, [68Ga]Ga-PentixaFor, with PET/CT to image metastatic triple-negative breast cancer. Adults with histologically confirmed TNBC and at least one measurable metastasis will undergo [68Ga]Ga-PentixaFor PET/CT and findings will be compared with prior [18F]FDG PET/CT and conventional imaging. The aim is to see if CXCR4 imaging identifies additional lesions or different uptake patterns that could change staging or treatment planning. Participants must give informed consent, have ECOG performance status <2, and meet pregnancy and contraception requirements.
Why it matters
Potential benefit: If successful, this imaging approach could improve detection of metastatic sites and help guide personalized treatment decisions for TNBC patients.
How similar studies have gone: CXCR4-targeted imaging has shown promising results in other cancers and preclinical models, but clinical data specifically in metastatic TNBC are limited and the approach remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.
2. Female or male, Age ≥ 18 years at time of study entry.
3. Primitive triple negative breast cancer proven histologically, defined according to the following criteria:
* Estrogen receptors \<10%.
* And progesterone receptors \<10%.
* And HER2 not amplified or not overexpressed.
4. Recurrence metastatic Breast Cancer or De Novo metastatic Breast Cancer documented by \[18F\]FDG PET/CT ± conventional imaging with at least one measurable metastasis according to PERCIST and/or RECIST.
5. ECOG performance status \< 2.
6. Negative serum/urine pregnancy test prior to \[68Ga\]Ga-PentixaFor administration for female patient of childbearing potential\*.
7. Consent to use a contraception method for at least 3 months after each administration of \[68Ga\]Ga-PentixaFor (as defined in Appendix 7 and according to local guidelines).
8. Adequate Organ function confirmed by laboratory tests results allowing for safe administration of \[68Ga\]Ga- PentixaFor:
Hematologic function: Absolute Neutrophil Count (ANC) of ≥ 1.5 x 109 /L, platelet count of ≥ 100 x 109 /L, and hemoglobin of ≥ 9 g/dL).
Hepatic function: AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases).
9. Renal function: Estimated Glomerular Filtration Rate (eGFR) ≥ 50 mL/min/1.73m², as calculated using the CKD-EPI or MDRD equation.Life expectancy at least 3 months.
10. Patient has valid health insurance.
11. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
* Note: a female participant of childbearing potential is a woman who is not permanently sterilized or not postmenopausal (postmenopausal is defined as 12 months with no menses without an alternative medical cause).
Exclusion Criteria:
1. History of another primary malignancy within the last 3 years before study entry except for basal cell carcinoma.
2. Impossibility to hold lying motionless at least 1 hour, or known claustrophobia.
3. Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator.
4. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
5. Pregnant, likely to be pregnant or breastfeeding woman.
6. Blood glucose \> 12mmol/L.
7. Renal insufficiency with GFR ≤ 45 mL/min/ 1.73 m².
8. Known hypersensitivity to any active pharmaceutical agent or constituent of the \[68Ga\]Ga-PentixaFor and/or \[18F\]FDG product.
9. Body weight of less than 48 kg.
10. Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.
11. Disorder precluding understanding of trial information or informed consent.
Where it's running
-
Institut de cancerologie de l'Ouest
Saint-Herblain, France Recruiting
Study contacts
- Principal investigator: CAROLINE ROUSSEAU, MD, PhD — Institut de Cancérologie de l'Ouest (ICO)
- Study coordinator: CAROLINE ROUSSEAU, MD, PhD
- Email: Caroline.Rousseau@ico.unicancer.fr
- Phone: +33 2 40 67 99 31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Personalized treatment after endocrine therapy failure in metastatic breast cancer
The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.
-
SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer
This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.
-
SMP-656 in HER2-positive advanced breast cancer after ADC therapy
This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer
This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.